 Receptor, ErbB-2
"Receptor, ErbB-2" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A cell surface protein-tyrosine kinase receptor that is overexpressed in a variety of ADENOCARCINOMAS. It has extensive homology to and heterodimerizes with the EGF RECEPTOR, the ERBB-3 RECEPTOR, and the ERBB-4 RECEPTOR. Activation of the erbB-2 receptor occurs through heterodimer formation with a ligand-bound erbB receptor family member.
| Descriptor ID |
D018719
|
| MeSH Number(s) |
D08.811.913.696.620.682.725.400.009.400 D12.776.543.750.630.009.400 D12.776.543.750.750.400.074.400 D12.776.624.664.700.642 D23.050.301.500.600.700 D23.050.705.552.600.550 D23.101.140.642
|
| Concept/Terms |
Receptor, ErbB-2- Receptor, ErbB-2
- ErbB-2 Receptor
- Antigens, CD340
- CD340 Antigens
- Proto-Oncogene Proteins c-erbB-2
- Proto Oncogene Proteins c erbB 2
- p185(c-neu)
- c-erbB-2 Protein
- c erbB 2 Protein
- erbB-2 Proto-Oncogene Protein
- Proto-Oncogene Protein, erbB-2
- erbB 2 Proto Oncogene Protein
- erbB-2 Receptor Protein-Tyrosine Kinase
- erbB 2 Receptor Protein Tyrosine Kinase
- neu Proto-Oncogene Protein
- Proto-Oncogene Protein, neu
- neu Proto Oncogene Protein
- HER-2 Proto-Oncogene Protein
- HER 2 Proto Oncogene Protein
- Proto-Oncogene Protein, HER-2
- Proto-Oncogene Protein HER-2
- Proto Oncogene Protein HER 2
- Receptors, erbB-2
- erbB-2 Receptors
- Neu Receptor
- Receptor, Neu
- Metastatic Lymph Node Gene 19 Protein
- Proto-oncogene Protein Neu
- Neu, Proto-oncogene Protein
- Proto-oncogene c-ErbB-2
- c-ErbB-2, Proto-oncogene
- Tyrosine Kinase-type Cell Surface Receptor HER2
- Tyrosine Kinase type Cell Surface Receptor HER2
- p185erbB2 Protein
- CD340 Antigen
- Oncogene Protein HER-2
- Oncogene Protein HER 2
- Proto-Oncogene Protein p185(neu)
|
Below are MeSH descriptors whose meaning is more general than "Receptor, ErbB-2".
- Chemicals and Drugs [D]
- Enzymes and Coenzymes [D08]
- Enzymes [D08.811]
- Transferases [D08.811.913]
- Phosphotransferases [D08.811.913.696]
- Phosphotransferases (Alcohol Group Acceptor) [D08.811.913.696.620]
- Protein Kinases [D08.811.913.696.620.682]
- Protein-Tyrosine Kinases [D08.811.913.696.620.682.725]
- Receptor Protein-Tyrosine Kinases [D08.811.913.696.620.682.725.400]
- ErbB Receptors [D08.811.913.696.620.682.725.400.009]
- Receptor, ErbB-2 [D08.811.913.696.620.682.725.400.009.400]
- Amino Acids, Peptides, and Proteins [D12]
- Proteins [D12.776]
- Membrane Proteins [D12.776.543]
- Receptors, Cell Surface [D12.776.543.750]
- Receptor Protein-Tyrosine Kinases [D12.776.543.750.630]
- ErbB Receptors [D12.776.543.750.630.009]
- Receptor, ErbB-2 [D12.776.543.750.630.009.400]
- Receptors, Peptide [D12.776.543.750.750]
- Receptors, Growth Factor [D12.776.543.750.750.400]
- ErbB Receptors [D12.776.543.750.750.400.074]
- Receptor, ErbB-2 [D12.776.543.750.750.400.074.400]
- Neoplasm Proteins [D12.776.624]
- Oncogene Proteins [D12.776.624.664]
- Proto-Oncogene Proteins [D12.776.624.664.700]
- Receptor, ErbB-2 [D12.776.624.664.700.642]
- Biological Factors [D23]
- Antigens [D23.050]
- Antigens, Surface [D23.050.301]
- Histocompatibility Antigens [D23.050.301.500]
- Minor Histocompatibility Antigens [D23.050.301.500.600]
- Receptor, ErbB-2 [D23.050.301.500.600.700]
- Isoantigens [D23.050.705]
- Histocompatibility Antigens [D23.050.705.552]
- Minor Histocompatibility Antigens [D23.050.705.552.600]
- Receptor, ErbB-2 [D23.050.705.552.600.550]
- Biomarkers [D23.101]
- Biomarkers, Tumor [D23.101.140]
- Receptor, ErbB-2 [D23.101.140.642]
Below are MeSH descriptors whose meaning is more specific than "Receptor, ErbB-2".
This graph shows the total number of publications written about "Receptor, ErbB-2" by people in this website by year, and whether "Receptor, ErbB-2" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 0 | 1 | 1 | | 1995 | 1 | 1 | 2 | | 1996 | 1 | 2 | 3 | | 1998 | 1 | 1 | 2 | | 1999 | 0 | 1 | 1 | | 2000 | 3 | 1 | 4 | | 2001 | 0 | 1 | 1 | | 2002 | 4 | 0 | 4 | | 2003 | 2 | 3 | 5 | | 2004 | 4 | 6 | 10 | | 2005 | 5 | 4 | 9 | | 2006 | 3 | 2 | 5 | | 2007 | 5 | 0 | 5 | | 2008 | 4 | 1 | 5 | | 2009 | 3 | 2 | 5 | | 2010 | 6 | 2 | 8 | | 2011 | 3 | 3 | 6 | | 2012 | 4 | 3 | 7 | | 2013 | 8 | 3 | 11 | | 2014 | 3 | 3 | 6 | | 2015 | 9 | 8 | 17 | | 2016 | 5 | 10 | 15 | | 2017 | 4 | 6 | 10 | | 2018 | 8 | 3 | 11 | | 2019 | 9 | 6 | 15 | | 2020 | 3 | 11 | 14 | | 2021 | 4 | 7 | 11 | | 2022 | 0 | 3 | 3 | | 2023 | 0 | 3 | 3 |
To return to the timeline, click here.
Below are the most recent publications written about "Receptor, ErbB-2" by people in Profiles.
-
Lipsyc-Sharf M, Jain E, Collins LC, Rosenberg SM, Ruddy KJ, Tamimi RM, Schapira L, Come SE, Peppercorn JM, Borges VF, Warner E, Snow C, Krop IE, Kim D, Weiss J, Zanudo JGT, Partridge AH, Wagle N, Waks AG. Genomics of ERBB2-Positive Breast Cancer in Young Women Before and After Exposure to Chemotherapy Plus Trastuzumab. JCO Precis Oncol. 2023 06; 7:e2300076.
-
Vemuru S, Huang J, Colborn K, Yoon Y, Huynh V, Leonard L, Ahrendt G, Christian N, Afghahi A, McLemore L, Sams S, Tevis S. Clinical implications of receptor conversions in breast cancer patients who have undergone neoadjuvant chemotherapy. Breast Cancer Res Treat. 2023 Jul; 200(2):247-256.
-
Lin NU, Murthy RK, Abramson V, Anders C, Bachelot T, Bedard PL, Borges V, Cameron D, Carey LA, Chien AJ, Curigliano G, DiGiovanna MP, Gelmon K, Hortobagyi G, Hurvitz SA, Krop I, Loi S, Loibl S, Mueller V, Oliveira M, Paplomata E, Pegram M, Slamon D, Zelnak A, Ramos J, Feng W, Winer E. Tucatinib vs Placebo, Both in Combination With Trastuzumab and Capecitabine, for Previously Treated ERBB2 (HER2)-Positive Metastatic Breast Cancer in Patients With Brain Metastases: Updated Exploratory Analysis of the HER2CLIMB Randomized Clinical Trial. JAMA Oncol. 2023 02 01; 9(2):197-205.
-
Bardia A, Mayer I, Winer E, Linden HM, Ma CX, Parker BA, Bellet M, Arteaga CL, Cheeti S, Gates M, Chang CW, Fredrickson J, Spoerke JM, Moore HM, Giltnane J, Friedman LS, Chow Maneval E, Chan I, Jhaveri K. The oral selective estrogen receptor degrader GDC-0810 (ARN-810) in postmenopausal women with hormone receptor-positive HER2-negative (HR?+?/HER2?-) advanced/metastatic breast cancer. Breast Cancer Res Treat. 2023 Jan; 197(2):319-331.
-
Osdoit M, Yau C, Symmans WF, Boughey JC, Ewing CA, Balassanian R, Chen YY, Krings G, Wallace AM, Zare S, Fadare O, Lancaster R, Wei S, Godellas CV, Tang P, Tuttle TM, Klein M, Sahoo S, Hieken TJ, Carter JM, Chen B, Ahrendt G, Tchou J, Feldman M, Tousimis E, Zeck J, Jaskowiak N, Sattar H, Naik AM, Lee MC, Rosa M, Khazai L, Rendi MH, Lang JE, Lu J, Tawfik O, Asare SM, Esserman LJ, Mukhtar RA. Association of Residual Ductal Carcinoma In Situ With Breast Cancer Recurrence in the Neoadjuvant I-SPY2 Trial. JAMA Surg. 2022 11 01; 157(11):1034-1041.
-
Roy-Chowdhuri S, Davies KD, Ritterhouse LL, Snow AN. ERBB2 (HER2) Alterations in Colorectal Cancer. J Mol Diagn. 2022 10; 24(10):1064-1066.
-
Rasti AR, Guimaraes-Young A, Datko F, Borges VF, Aisner DL, Shagisultanova E. PIK3CA Mutations Drive Therapeutic Resistance in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer. JCO Precis Oncol. 2022 03; 6:e2100370.
-
Curigliano G, Mueller V, Borges V, Hamilton E, Hurvitz S, Loi S, Murthy R, Okines A, Paplomata E, Cameron D, Carey LA, Gelmon K, Hortobagyi GN, Krop I, Loibl S, Pegram M, Slamon D, Ramos J, Feng W, Winer E. Tucatinib versus placebo added to trastuzumab and capecitabine for patients with pretreated HER2+ metastatic breast cancer with and without brain metastases (HER2CLIMB): final overall survival analysis. Ann Oncol. 2022 03; 33(3):321-329.
-
Clark AS, Yau C, Wolf DM, Petricoin EF, van 't Veer LJ, Yee D, Moulder SL, Wallace AM, Chien AJ, Isaacs C, Boughey JC, Albain KS, Kemmer K, Haley BB, Han HS, Forero-Torres A, Elias A, Lang JE, Ellis ED, Yung R, Tripathy D, Nanda R, Wulfkuhle JD, Brown-Swigart L, Gallagher RI, Helsten T, Roesch E, Ewing CA, Alvarado M, Crane EP, Buxton M, Clennell JL, Paoloni M, Asare SM, Wilson A, Hirst GL, Singhrao R, Steeg K, Asare A, Matthews JB, Berry S, Sanil A, Melisko M, Perlmutter J, Rugo HS, Schwab RB, Symmans WF, Hylton NM, Berry DA, Esserman LJ, DeMichele AM. Neoadjuvant T-DM1/pertuzumab and paclitaxel/trastuzumab/pertuzumab for HER2+ breast cancer in the adaptively randomized I-SPY2 trial. Nat Commun. 2021 11 05; 12(1):6428.
-
Symmans WF, Yau C, Chen YY, Balassanian R, Klein ME, Pusztai L, Nanda R, Parker BA, Datnow B, Krings G, Wei S, Feldman MD, Duan X, Chen B, Sattar H, Khazai L, Zeck JC, Sams S, Mhawech-Fauceglia P, Rendi M, Sahoo S, Ocal IT, Fan F, LeBeau LG, Vinh T, Troxell ML, Chien AJ, Wallace AM, Forero-Torres A, Ellis E, Albain KS, Murthy RK, Boughey JC, Liu MC, Haley BB, Elias AD, Clark AS, Kemmer K, Isaacs C, Lang JE, Han HS, Edmiston K, Viscusi RK, Northfelt DW, Khan QJ, Leyland-Jones B, Venters SJ, Shad S, Matthews JB, Asare SM, Buxton M, Asare AL, Rugo HS, Schwab RB, Helsten T, Hylton NM, van 't Veer L, Perlmutter J, DeMichele AM, Yee D, Berry DA, Esserman LJ. Assessment of Residual Cancer Burden and Event-Free Survival in Neoadjuvant Treatment for High-risk Breast Cancer: An Analysis of Data From the I-SPY2 Randomized Clinical Trial. JAMA Oncol. 2021 Nov 01; 7(11):1654-1663.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|